A client presents to the emergency department with a puncture wound sustained 48 hours ago.

Assessment findings include: increasing localized pain, erythema extending beyond the wound margins, temperature 38.6 C (101.5 F), WBC 16,200/mm with 10 percent bands, and blood pressure trending down from baseline.

The nurse is analyzing whether the client's condition represents a localized inflammatory response or progression to a systemic inflammatory state.

Which pathophysiologic processes should the nurse identify as contributing to the client's current condition? (Select all that apply).

Choice A rationale

The activation of macrophages is primarily a function of T helper cells, specifically the Th subset. These T cells release cytokines such as interferon-gamma, which enhances the phagocytic and microbicidal activity of macrophages. While B cells are part of the adaptive immune system and can act as antigen-presenting cells, their primary specialized role in the immune hierarchy is not the direct stimulation of macrophage effector functions but rather the transition into antibody-secreting plasma cells.

Choice B rationale

The recognition of Major Histocompatibility Complex I molecules is a specific function of CD8+ cytotoxic T lymphocytes. Every nucleated cell in the human body expresses MHC I to display endogenous antigens. Cytotoxic T cells use their T-cell receptors to scan these molecules for viral or tumor proteins. B cells, conversely, recognize intact, soluble antigens through their membrane-bound immunoglobulin receptors, which do not require the antigen to be presented on an MHC I molecule for initial binding.

Choice C rationale

The direct killing of infected or cancerous cells is performed by cytotoxic T cells and Natural Killer cells through the release of perforins and granzymes. These substances induce apoptosis in the target cell. B cells do not possess these cytolytic granules and do not engage in cell-to-cell combat. Instead, they provide humoral immunity, which involves the systemic distribution of proteins that neutralize pathogens remotely, rather than requiring the B cell to physically destroy the infected host cell.

Choice D rationale

The hallmark function of B lymphocytes is their differentiation into plasma cells, which are specialized factories for the production of antibodies or immunoglobulins. These antibodies circulate in the blood and lymph, binding specifically to antigens on the surface of pathogens like bacteria and viruses. This binding can neutralize the pathogen, opsonize it for easier phagocytosis by neutrophils, or activate the complement system. This humoral response is essential for long-term immunity and the effectiveness of vaccinations.

Choice A rationale

Anosmia refers to the complete loss of the sense of smell, which can significantly impact the perception of flavor but does not directly cause food to taste bitter or unpleasant. While smell contributes to about 80 percent of what we perceive as taste, the specific complaint of a distorted or foul taste in the mouth is a gustatory rather than an olfactory deficit. Therefore, anosmia does not accurately describe the symptom of food tasting bitter during chemotherapy treatments.

Choice B rationale

Dysgeusia is a condition characterized by a persistent distortion of the sense of taste, often manifesting as a metallic, salty, or bitter sensation. In oncology patients, chemotherapy drugs can damage the rapidly dividing taste bud cells or be secreted into the saliva, altering the chemical environment of the mouth. This leads to the unpleasant and bitter taste reported by the patient. It is a common side effect that can lead to decreased oral intake and nutritional deficiencies.

Choice C rationale

Ageusia is the complete loss of taste functions, meaning the individual cannot detect any of the basic tastes such as sweet, sour, salty, or bitter. The patient in this scenario is still able to perceive taste, but the perception is distorted and unpleasant rather than absent. Since the patient specifically describes the taste as bitter rather than stating they have no taste sensation at all, ageusia is an incorrect classification for this specific sensory alteration during chemotherapy.

Choice D rationale

Hypogeusia is a reduced ability to taste, where the intensity of all taste sensations is diminished but not completely gone. While a patient with hypogeusia might find food bland, they do not typically report that food tastes specifically bitter or unpleasant as a result of the condition itself. The patient's report of a distinct, foul, and bitter taste points toward a qualitative distortion of taste, which is the defining characteristic of dysgeusia rather than a simple quantitative reduction.